0001209191-23-042984.txt : 20230720 0001209191-23-042984.hdr.sgml : 20230720 20230720210351 ACCESSION NUMBER: 0001209191-23-042984 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230720 FILED AS OF DATE: 20230720 DATE AS OF CHANGE: 20230720 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FMR LLC CENTRAL INDEX KEY: 0000315066 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41747 FILM NUMBER: 231100908 BUSINESS ADDRESS: STREET 1: 245 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6175706339 MAIL ADDRESS: STREET 1: 245 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02210 FORMER NAME: FORMER CONFORMED NAME: FMR CORP DATE OF NAME CHANGE: 19920717 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Turnstone Biologics Corp. CENTRAL INDEX KEY: 0001764974 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 832909368 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 920 BROADWAY STREET 2: 16TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: 347-897-5988 MAIL ADDRESS: STREET 1: 920 BROADWAY STREET 2: 16TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10010 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2023-07-20 0 0001764974 Turnstone Biologics Corp. TSBX 0000315066 FMR LLC 245 SUMMER STREET BOSTON MA 02210 0 0 1 1 See Remark 1 Series D Preferred Stock Common Stock 91663 I F-Prime Capital Partners Healthcare Fund V LP Series C Preferred Stock Common Stock 106496 I F-Prime Capital Partners Healthcare Fund V LP Series B-2 Preferred Stock Common Stock 150809 I F-Prime Capital Partners Healthcare Fund V LP Series B-1 Preferred Stock Common Stock 483684 I F-Prime Capital Partners Healthcare Fund V LP Series B-2 Preferred Stock Common Stock 296396 I Impresa Fund III Limited Partnership Series B-2 Preferred Stock Common Stock 4939 I F-Prime Capital Partners Healthcare Advisors Fund V LP The Series B-1, B-2, C, and D Preferred Shares are convertible on a 1-for-1 basis into the number of shares of Common Stock as shown in column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering without payment or further consideration, and have no expiration date. Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: The general partner of F-Prime Capital Partners Healthcare Fund V LP is F-Prime Capital Partners Healthcare Advisors Fund V LP (FPCPHA). FPCPHA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson 2023-07-20